Abstract
The DXd ADC technology is an innovative platform that combines a DNA topoisomerase I（TOP1） inhibitor, specifically the proprietary exatecan derivative（DXd）, with a cathepsin-cleavable peptide linker, achieving a high drug-to-antibody ratio and enhanced stability in the blood circulation. The first DXd ADC, trastuzumab deruxtecan（T-DXd）, was initially approved for HER2-positive breast cancer and later expanded its indications to include HER2-low breast cancer and HER2-positive solid tumors across multiple cancer types, offering new treatment options in patients with unmet medical needs. Following T-DXd, the use of TOP1 inhibitors in ADCs has become a growing trend, and the DXd ADC platform is currently advancing clinical trials for five new ADCs. New generation ADCs are now exploring the use of more potent payloads or alternative mechanisms of action to overcome the drug resistance, etc. These novel technologies are expected to bring about new paradigm shift in cancer treatment, providing new therapeutic options for patients.
